Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChrysalis Inves Regulatory News (CHRY)

Share Price Information for Chrysalis Inves (CHRY)

Share Price is delayed by 15 minutes
Get Live Data
79.40    -1.00 (-1.24%)
Bid:
79.30
Ask:
79.60
Spread: 0.30 (0.378%)
Market Cap: £381.89m
CHRY Live PriceLast checked at - London Stock Exchange

Intraday Chrysalis Inves Share Chart

Update note from QuotedData

27 Feb 2025 15:39

RNS Number : 7680Y
Chrysalis Investments Limited
27 February 2025
 

Chrysalis Investments - Update from QuotedData

27th February 2025

Return to form

Chrysalis Investments Limited (CHRY) has experienced decent net asset value (NAV) and share price growth recently. With the bulk of the proceeds from the disposals of Graphcore and Featurespace received, and the term loan facility drawn down, CHRY is making good progress with its share buyback programme (see page 4). As of publication, 46,183,261 shares had been bought back, around 7.8% of CHRY's issued share capital, and this is boosting its NAV. CHRY has now returned about £45m of its £100m target and is well placed to press ahead with this, as it had a total liquidity position (available cash and credit) of approximately £144m at end December 2024.

The bulk of the portfolio is performing well - in its recent results, CHRY said that all portfolio companies have seen profits rise or losses narrow - and Klarna's IPO still looks likely at some point this year. While there is a good case that it might soon be time to make new investments, the focus for 2025 will remain on narrowing the discount to NAV, which is in much better shape than it was a year ago, but still has room for improvement.

Full Research:

https://quoteddata.com/research/chrysalis-investments-return-to-form-qd/

This research is also available free on our website www.quoteddata.com where you will also find news, performance data and factsheets on every London listed Investment Company. QuotedData writes and distributes research on a number of quoted companies, facilitates meetings between those companies and existing and potential investors and assists in raising additional capital where required.

NB: Marten & Co was paid to produce this note Chrysalis Investments Limited, and it is for information purposes only. It is not intended to encourage the reader to deal in the security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which is authorised and regulated by the Financial Conduct Authority. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of the Financial Conduct Authority.

QUOTEDDATA50 Gresham Street | London EC2V 7AYTel: +44 (0) 20 3691 9430

www.quoteddata.com | research@quoteddata.com | www.martenandco.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFZGZZKNRGKZM
Date   Source Headline
7th Jun 20227:00 amRNSNew Independent Valuation Committee
30th May 20227:00 amRNSDirector/PDMR Shareholding
23rd May 20227:00 amRNSQuarterly Net Asset Value and Trading Update
13th May 202211:40 amRNSDirector/PDMR Shareholding
14th Apr 20227:00 amRNSInterim NAV Announcement
17th Mar 202211:34 amRNSHolding(s) in Company
21st Feb 20227:00 amRNSQuarterly NAV Announcement and Trading Update
18th Feb 20222:21 pmRNSPublication of a Supplementary Prospectus
18th Feb 20227:00 amRNSResult of AGM
10th Feb 20224:15 pmRNSDirector/PDMR Shareholding
4th Feb 20224:52 pmRNSCorrection to AGM Resolution No. 11
3rd Feb 20223:19 pmRNSDirector/PDMR Shareholding
1st Feb 20222:06 pmRNSPortfolio Update
1st Feb 20227:00 amRNSNotice of AGM
31st Jan 20224:19 pmRNSHolding(s) in Company
31st Jan 202210:59 amRNSHolding(s) in Company
26th Jan 20227:00 amRNSAnnual Financial Report
16th Dec 202111:24 amRNSHolding(s) in Company
13th Dec 20217:00 amRNSResults of Capital Raise
1st Dec 20217:01 amRNSPrimaryBid Offer
1st Dec 20217:00 amRNSProposed Placing
29th Nov 20217:01 amRNSUpdate on Performance Fee Arrangements
29th Nov 20217:00 amRNSNet Asset Value(s) and Trading Update
18th Oct 20212:39 pmRNSDirector/PDMR Shareholding
18th Oct 20212:36 pmRNSDirector/PDMR Shareholding
11th Oct 20217:00 amRNSDepositary Business Transfer
17th Sep 20211:12 pmRNSHolding(s) in Company
20th Aug 20217:00 amRNSQuarterly NAV Announcement
19th Aug 20217:00 amRNSPortfolio Update
17th Aug 202111:29 amRNSPortfolio Update
5th Aug 20214:33 pmRNSUK Government Engagement
29th Jul 20217:00 amRNSPortfolio Update
7th Jul 202111:58 amRNSPortfolio Update
6th Jul 20217:00 amRNSPortfolio Update
30th Jun 20217:00 amRNSInterim Results to 31 March 2021
29th Jun 20217:00 amRNSPortfolio Update
28th Jun 20217:00 amRNSPortfolio Update
25th Jun 20211:02 pmRNSHolding(s) in Company
24th Jun 20217:00 amRNSPortfolio Update
10th Jun 20212:17 pmRNSPortfolio Update
1st Jun 20212:38 pmRNSPortfolio Update
1st Jun 20217:00 amRNSNAV Update
26th May 20217:00 amRNSNet Asset Value(s)
11th May 20211:20 pmRNSDirector/PDMR Shareholding
6th May 20217:00 amRNSChange of AIFM
1st Apr 20215:44 pmRNSHolding(s) in Company
1st Apr 20214:17 pmRNSHolding(s) in Company
26th Mar 20212:57 pmRNSDirector/PDMR Shareholding
26th Mar 20217:00 amRNSResult of Initial Issue
10th Mar 20217:00 amRNSPlacing Programme, Issue,Revolving Credit Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.